Follow RSS for latest reports on this topicGilotrif (Afatinib) - Market Research and Reports

GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.

Website: http://www.gilotrif.com/

Manufacturer: Boehringer Ingelheim

BioPortfolio's Easy Ordering System

  1. Search for the report you need from our store
  2. Make online payment with our easy checkout process
  3. Receive PDF report via email

Easy Online Payment or Pro Forma Invoice

We accept the following credit cards...



or can supply a pro-forma invoice if required.

Additional Searches

You may also like to search separately for: Gilotrif (Afatinib)

We Stock...

{STICKYFOOTERMOBILE}